Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes
To evaluate the effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure (IOP) in monkey eyes with unilateral laser-induced glaucoma. A multiple-dose study was performed in 8 glaucomatous monkey eyes. One 50 microl drop of CS-088, 2% or 4%, was topically applied to the glauc...
Gespeichert in:
| Veröffentlicht in: | Experimental eye research 2005-05, Vol.80 (5), p.629-632 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 632 |
|---|---|
| container_issue | 5 |
| container_start_page | 629 |
| container_title | Experimental eye research |
| container_volume | 80 |
| creator | Wang, Rong-Fang Podos, Steven M Mittag, Thomas W Yokoyoma, Tomihisa |
| description | To evaluate the effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure (IOP) in monkey eyes with unilateral laser-induced glaucoma. A multiple-dose study was performed in 8 glaucomatous monkey eyes. One 50 microl drop of CS-088, 2% or 4%, was topically applied to the glaucomatous eye at 9:30 a.m. and 3:30 p.m. for 5 consecutive days. IOP was measured hourly for 6 hours beginning at 9:30 a.m. for one baseline day, one vehicle-treated day, and daily for 5 days of treatment with CS-088. The washout period between the two drug concentrations was at least 2 weeks. Twice daily administration of 2 % CS-088 for 5 days did not reduce the IOP until the third dose on day 2 of the treatment regimen. A significant (p |
| doi_str_mv | 10.1016/j.exer.2004.11.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67803276</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67803276</sourcerecordid><originalsourceid>FETCH-LOGICAL-c282t-7fac40af83912621d69ffc5997f0f7882bd50e2a783c0b874b48256d6bca98c63</originalsourceid><addsrcrecordid>eNpFkEtrwzAQhHVoadK0f6CHolNPsbuSX_IxhPQBgR6anoUsr4JT20olGZp_X5sECgsLuzPD8BHywCBmwPLnQ4y_6GIOkMaMxcD4FZkDsDRKRZLNyK33BwBI0iK9ITOWiZyzvJyTbmMM6kCtoevPCIRYUtWPs29swN43PV3tGHWo8RisGx9B7W3f-LCktqdNH5yyemiVo0eH3g8OxyPdt2rQtlPBDp52tv_GE8UT-jtybVTr8f6yF-TrZbNbv0Xbj9f39WobaS54iAqjdArKiKRkfCxa56UxOivLwoAphOBVnQFyVYhEQyWKtEoFz_I6r7Qqhc6TBXk65x6d_RnQB9k1XmPbqh7HSjIvBCS8mIT8LNTOeu_QyKNrOuVOkoGcwMqDnMDKCaxkTI5gR9PjJX2oOqz_LReqyR8963fI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67803276</pqid></control><display><type>article</type><title>Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Wang, Rong-Fang ; Podos, Steven M ; Mittag, Thomas W ; Yokoyoma, Tomihisa</creator><creatorcontrib>Wang, Rong-Fang ; Podos, Steven M ; Mittag, Thomas W ; Yokoyoma, Tomihisa</creatorcontrib><description>To evaluate the effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure (IOP) in monkey eyes with unilateral laser-induced glaucoma. A multiple-dose study was performed in 8 glaucomatous monkey eyes. One 50 microl drop of CS-088, 2% or 4%, was topically applied to the glaucomatous eye at 9:30 a.m. and 3:30 p.m. for 5 consecutive days. IOP was measured hourly for 6 hours beginning at 9:30 a.m. for one baseline day, one vehicle-treated day, and daily for 5 days of treatment with CS-088. The washout period between the two drug concentrations was at least 2 weeks. Twice daily administration of 2 % CS-088 for 5 days did not reduce the IOP until the third dose on day 2 of the treatment regimen. A significant (p<0.02) reduction in IOP began 1 hour after the third dose, and lasted for 3 hours. The maximum reduction in IOP was 5.3+/- 0.8 (mean+/-SEM) mmHg (15%) (p<0.001), with the longest duration of IOP reduction of at least 6 hours after dosing on day 5. The 4% dose of CS-088 reduced (p<0.05) IOP from 1 to 5 hours after the first dose. The maximum reduction in IOP was 6.9+/-1.0 mmHg (20%), with the longest duration of IOP reduction of at least 18 hours after administration on day 5. Both 2% and 4% CS-088 showed enhancement of the ocular hypotensive effect with repeated dosing. 4% CS-088 produced greater (p<0.05) IOP reduction with longer duration of action than 2%. Topically applied CS-088, a new antagonist drug at the angiotensin AT1 receptor, reduced IOP in glaucomatous monkey eyes in a dose-dependent manner.</description><identifier>ISSN: 0014-4835</identifier><identifier>DOI: 10.1016/j.exer.2004.11.012</identifier><identifier>PMID: 15862169</identifier><language>eng</language><publisher>England</publisher><subject>Administration, Topical ; Animals ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Glaucoma - drug therapy ; Imidazoles - therapeutic use ; Intraocular Pressure - drug effects ; Lasers ; Macaca fascicularis ; Models, Animal ; Receptor, Angiotensin, Type 1 - drug effects ; Tetrazoles - therapeutic use ; Tonometry, Ocular</subject><ispartof>Experimental eye research, 2005-05, Vol.80 (5), p.629-632</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c282t-7fac40af83912621d69ffc5997f0f7882bd50e2a783c0b874b48256d6bca98c63</citedby><cites>FETCH-LOGICAL-c282t-7fac40af83912621d69ffc5997f0f7882bd50e2a783c0b874b48256d6bca98c63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15862169$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Rong-Fang</creatorcontrib><creatorcontrib>Podos, Steven M</creatorcontrib><creatorcontrib>Mittag, Thomas W</creatorcontrib><creatorcontrib>Yokoyoma, Tomihisa</creatorcontrib><title>Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes</title><title>Experimental eye research</title><addtitle>Exp Eye Res</addtitle><description>To evaluate the effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure (IOP) in monkey eyes with unilateral laser-induced glaucoma. A multiple-dose study was performed in 8 glaucomatous monkey eyes. One 50 microl drop of CS-088, 2% or 4%, was topically applied to the glaucomatous eye at 9:30 a.m. and 3:30 p.m. for 5 consecutive days. IOP was measured hourly for 6 hours beginning at 9:30 a.m. for one baseline day, one vehicle-treated day, and daily for 5 days of treatment with CS-088. The washout period between the two drug concentrations was at least 2 weeks. Twice daily administration of 2 % CS-088 for 5 days did not reduce the IOP until the third dose on day 2 of the treatment regimen. A significant (p<0.02) reduction in IOP began 1 hour after the third dose, and lasted for 3 hours. The maximum reduction in IOP was 5.3+/- 0.8 (mean+/-SEM) mmHg (15%) (p<0.001), with the longest duration of IOP reduction of at least 6 hours after dosing on day 5. The 4% dose of CS-088 reduced (p<0.05) IOP from 1 to 5 hours after the first dose. The maximum reduction in IOP was 6.9+/-1.0 mmHg (20%), with the longest duration of IOP reduction of at least 18 hours after administration on day 5. Both 2% and 4% CS-088 showed enhancement of the ocular hypotensive effect with repeated dosing. 4% CS-088 produced greater (p<0.05) IOP reduction with longer duration of action than 2%. Topically applied CS-088, a new antagonist drug at the angiotensin AT1 receptor, reduced IOP in glaucomatous monkey eyes in a dose-dependent manner.</description><subject>Administration, Topical</subject><subject>Animals</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Glaucoma - drug therapy</subject><subject>Imidazoles - therapeutic use</subject><subject>Intraocular Pressure - drug effects</subject><subject>Lasers</subject><subject>Macaca fascicularis</subject><subject>Models, Animal</subject><subject>Receptor, Angiotensin, Type 1 - drug effects</subject><subject>Tetrazoles - therapeutic use</subject><subject>Tonometry, Ocular</subject><issn>0014-4835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtrwzAQhHVoadK0f6CHolNPsbuSX_IxhPQBgR6anoUsr4JT20olGZp_X5sECgsLuzPD8BHywCBmwPLnQ4y_6GIOkMaMxcD4FZkDsDRKRZLNyK33BwBI0iK9ITOWiZyzvJyTbmMM6kCtoevPCIRYUtWPs29swN43PV3tGHWo8RisGx9B7W3f-LCktqdNH5yyemiVo0eH3g8OxyPdt2rQtlPBDp52tv_GE8UT-jtybVTr8f6yF-TrZbNbv0Xbj9f39WobaS54iAqjdArKiKRkfCxa56UxOivLwoAphOBVnQFyVYhEQyWKtEoFz_I6r7Qqhc6TBXk65x6d_RnQB9k1XmPbqh7HSjIvBCS8mIT8LNTOeu_QyKNrOuVOkoGcwMqDnMDKCaxkTI5gR9PjJX2oOqz_LReqyR8963fI</recordid><startdate>200505</startdate><enddate>200505</enddate><creator>Wang, Rong-Fang</creator><creator>Podos, Steven M</creator><creator>Mittag, Thomas W</creator><creator>Yokoyoma, Tomihisa</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200505</creationdate><title>Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes</title><author>Wang, Rong-Fang ; Podos, Steven M ; Mittag, Thomas W ; Yokoyoma, Tomihisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c282t-7fac40af83912621d69ffc5997f0f7882bd50e2a783c0b874b48256d6bca98c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Administration, Topical</topic><topic>Animals</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Glaucoma - drug therapy</topic><topic>Imidazoles - therapeutic use</topic><topic>Intraocular Pressure - drug effects</topic><topic>Lasers</topic><topic>Macaca fascicularis</topic><topic>Models, Animal</topic><topic>Receptor, Angiotensin, Type 1 - drug effects</topic><topic>Tetrazoles - therapeutic use</topic><topic>Tonometry, Ocular</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Rong-Fang</creatorcontrib><creatorcontrib>Podos, Steven M</creatorcontrib><creatorcontrib>Mittag, Thomas W</creatorcontrib><creatorcontrib>Yokoyoma, Tomihisa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental eye research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Rong-Fang</au><au>Podos, Steven M</au><au>Mittag, Thomas W</au><au>Yokoyoma, Tomihisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes</atitle><jtitle>Experimental eye research</jtitle><addtitle>Exp Eye Res</addtitle><date>2005-05</date><risdate>2005</risdate><volume>80</volume><issue>5</issue><spage>629</spage><epage>632</epage><pages>629-632</pages><issn>0014-4835</issn><abstract>To evaluate the effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure (IOP) in monkey eyes with unilateral laser-induced glaucoma. A multiple-dose study was performed in 8 glaucomatous monkey eyes. One 50 microl drop of CS-088, 2% or 4%, was topically applied to the glaucomatous eye at 9:30 a.m. and 3:30 p.m. for 5 consecutive days. IOP was measured hourly for 6 hours beginning at 9:30 a.m. for one baseline day, one vehicle-treated day, and daily for 5 days of treatment with CS-088. The washout period between the two drug concentrations was at least 2 weeks. Twice daily administration of 2 % CS-088 for 5 days did not reduce the IOP until the third dose on day 2 of the treatment regimen. A significant (p<0.02) reduction in IOP began 1 hour after the third dose, and lasted for 3 hours. The maximum reduction in IOP was 5.3+/- 0.8 (mean+/-SEM) mmHg (15%) (p<0.001), with the longest duration of IOP reduction of at least 6 hours after dosing on day 5. The 4% dose of CS-088 reduced (p<0.05) IOP from 1 to 5 hours after the first dose. The maximum reduction in IOP was 6.9+/-1.0 mmHg (20%), with the longest duration of IOP reduction of at least 18 hours after administration on day 5. Both 2% and 4% CS-088 showed enhancement of the ocular hypotensive effect with repeated dosing. 4% CS-088 produced greater (p<0.05) IOP reduction with longer duration of action than 2%. Topically applied CS-088, a new antagonist drug at the angiotensin AT1 receptor, reduced IOP in glaucomatous monkey eyes in a dose-dependent manner.</abstract><cop>England</cop><pmid>15862169</pmid><doi>10.1016/j.exer.2004.11.012</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-4835 |
| ispartof | Experimental eye research, 2005-05, Vol.80 (5), p.629-632 |
| issn | 0014-4835 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67803276 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Administration, Topical Animals Dose-Response Relationship, Drug Drug Administration Schedule Female Glaucoma - drug therapy Imidazoles - therapeutic use Intraocular Pressure - drug effects Lasers Macaca fascicularis Models, Animal Receptor, Angiotensin, Type 1 - drug effects Tetrazoles - therapeutic use Tonometry, Ocular |
| title | Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T09%3A03%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20CS-088,%20an%20angiotensin%20AT1%20receptor%20antagonist,%20on%20intraocular%20pressure%20in%20glaucomatous%20monkey%20eyes&rft.jtitle=Experimental%20eye%20research&rft.au=Wang,%20Rong-Fang&rft.date=2005-05&rft.volume=80&rft.issue=5&rft.spage=629&rft.epage=632&rft.pages=629-632&rft.issn=0014-4835&rft_id=info:doi/10.1016/j.exer.2004.11.012&rft_dat=%3Cproquest_cross%3E67803276%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67803276&rft_id=info:pmid/15862169&rfr_iscdi=true |